ADRA1D
MOLECULAR TARGETadrenoceptor alpha 1D
ADRA1D (adrenoceptor alpha 1D) is targeted by 40 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting ADRA1D
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Phentolamine | 3.76 | 42 |
| 2 | Yohimbine | 3.18 | 23 |
| 3 | Tamsulosin | 3.14 | 22 |
| 4 | Norepinephrine Precursor of epinephrine that is secreted by | 3.09 | 21 |
| 5 | Idazoxan | 2.94 | 18 |
| 6 | Clonidine | 2.56 | 12 |
| 7 | Oxymetazoline | 2.48 | 11 |
| 8 | Epinephrine | 2.30 | 9 |
| 9 | Mianserin | 2.20 | 8 |
| 10 | Buspirone | 2.20 | 8 |
| 11 | Piperoxan | 2.20 | 8 |
| 12 | Indoramin | 1.95 | 6 |
| 13 | Phenylephrine | 1.79 | 5 |
| 14 | Fluoxetine | 1.61 | 4 |
| 15 | Quetiapine Fumarate | 1.61 | 4 |
| 16 | Aripiprazole | 1.61 | 4 |
| 17 | Naphazoline | 1.61 | 4 |
| 18 | Dihydroergotamine | 1.39 | 3 |
| 19 | Methoxamine | 1.39 | 3 |
| 20 | Tolazoline | 1.39 | 3 |
| 21 | Carvedilol | 1.10 | 2 |
| 22 | Dexmedetomidine | 1.10 | 2 |
| 23 | eliprodil | 1.10 | 2 |
| 24 | Labetalol | 1.10 | 2 |
| 25 | Phenoxybenzamine | 1.10 | 2 |
| 26 | Platelet Activating Factor | 1.10 | 2 |
| 27 | Trazodone | 1.10 | 2 |
| 28 | Amlodipine | 0.69 | 1 |
| 29 | Losartan | 0.69 | 1 |
| 30 | amn082 | 0.69 | 1 |
| 31 | Atenolol | 0.69 | 1 |
| 32 | Cyproheptadine | 0.69 | 1 |
| 33 | Dihydroergotamine | 0.69 | 1 |
| 34 | Guanabenz | 0.69 | 1 |
| 35 | Hydroxyzine | 0.69 | 1 |
| 36 | Isoproterenol Isopropyl analog of EPINEPHRINE; beta-sympathomimetic that acts on | 0.69 | 1 |
| 37 | Loxapine | 0.69 | 1 |
| 38 | Metergoline | 0.69 | 1 |
| 39 | Pergolide | 0.69 | 1 |
| 40 | Phenylpropanolamine | 0.69 | 1 |
About ADRA1D as a Drug Target
ADRA1D (adrenoceptor alpha 1D) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 40 compounds with documented ADRA1D interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
ADRA1D inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.